Germany
Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company, established in 2016, with a focus on the discovery and development of RNA-based therapeutics to address cardiac diseases. Operating from its headquarters in Germany, Cardior leverages distinctive non-coding RNAs to innovate treatments that target the root causes of heart dysfunctions.
The company's mission aligns with its slogan: "Cardior develops RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart." This strategic approach aspires to bring transformative solutions to patients worldwide.
In its pursuit of advancing cardiac treatment, Cardior secured a €64.00M Series B investment on August 25, 2021. This funding round attracted significant investors, including BioMed Partners, Coparion, and Bristol-Myers Squibb, among others. As of May 2, 2024, Cardior operates as a wholly-owned subsidiary of Novo Nordisk Region Europe A/S, signaling strong industry validation and potential for substantial impact.
HAYA Therapeutics
